摘要
报道阿普唑仑(男性16,女性14,年龄30.1±s 1.9a,剂量2.4mg±1.2mg/d,6wk)和米帕明(男性14,女性12,年龄28.2±1.7a,剂量175mg±25mg/d,6wk)治疗抑郁性神经症56例的对照试验。结果2组治疗前到结束HAMD,SDS总分降低差别显著(P<0.01),而药物显效时间、治疗总有效率2组差别不显著。TESS评分阿普唑仑的不良反应显著少于米帕明。
This paper reports a control trial of alprazolam (M 16, F 14, age 30.1 ±s1.9a, dose 2.4mg ± 1.2mg/d,6wk) vs imipramine (M 14, F 12, age 28.2 ± 1.7a, dose 175mg ± 25mg/d, 6wk)in treating patients with depressive neurosis. At the end of therapy, the total scores on HAMD and SDS of both groups decreased (F<0. 01). The period from taking drugs to emergence of antidepressive effects and total response rates did not show significant differences between the 2 groups. TESS test showed that adverse reactions of alprazolam were less than those of imipramine.
出处
《新药与临床》
CSCD
北大核心
1993年第6期348-350,共3页
关键词
阿普唑仑
米帕明
抑郁障碍症
alprazolam
imipramine
depressive disorder
